The purpose of comparative effectiveness research (CER) is to provide information that helps clinicians and patients to choose the best treatments for a given individual with a specific medical ...

The main lessons for the United States from the experience of NICE relate to how the institute has gathered, synthesized, and used information on the clinical and cost effectiveness of health care ...

Comparative effectiveness research has been the target of recurrent criticism in some political circles, with opponents claiming it’s the “gateway to rationing” or it encourages “cookbook medicine.” ...

John Zalcberg undertook this work while on sabbatical at the National Institute for Clinical Studies but other than in kind support, he did not receive funds from that organisation. The evidence ...

A new national initiative in comparative effectiveness research (CER) is part of a broad and long-term evolution toward greater reliance on scientific evidence in clinical practice and medical policy.

Charged with ensuring that research produces useful evidence to inform health decisions, the Patient-Centered Outcomes Research Institute (PCORI) requires investigators to engage patients and other ...

Rigorous scientific standards are needed to address the challenge of providing information on the real-world effects of treatments and procedures. With enactment of healthcare reform legislation now a ...

A research-driven evaluation assessing the comparative effectiveness of phosphodiesterase type 5 (PDE5) inhibitors is contributing to ongoing clinical discourse around vascular-mediated functional ...

With the Patient Protection and Affordable Care Act ("ACA") set to dramatically increase access to medical care, the problem of rising costs will move center stage in health law and policy discussions ...

The complexity of glycemic management in type 2 diabetes mellitus (T2DM) has increased dramatically in the past 15 years. In 1995, the drugs available for treatment of T2DM were insulin and ...

On February 17, 2009, President Barack Obama signed into law an initiative providing $1.1 billion to support research on the comparative effectiveness of drugs, medical devices, surgical procedures, ...